A chemical compound that blocks receptors for advanced glycan end-products (RAGE) appeared to reduce inflammation associated with COPD and other lung diseases in a mouse model.
The researchers injected mice with an in vivo COPD inducer and the RAGE antagonist FPS-ZM1. Then they assessed the infiltrated inflammatory cells and their production of cytokines. Cellular expression of RAGE, initiating inflammatory response, and soluble RAGE, acting as a “decoy,” was determined in protein, serum, and bronchoalveolar lavage fluid in the mice, as well as in the serum of human donors and patients with COPD.
Get the whole story at www.sciencedaily.com
